New hope for advanced kidney cancer patients in drug combination trial

NCT ID NCT05805501

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

Summary

This study is testing the safety of two new drug combinations for people with advanced kidney cancer that cannot be removed by surgery. It compares a new immunotherapy drug (tobemstomig) plus a targeted therapy (axitinib) against the current standard treatment. The goal is to see if these new combinations can help control the cancer with manageable side effects for the 199 participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Barts & London School of Med

London, EC1A 7BE, United Kingdom
Beijing Cancer Hospital

Beijing, 100142, China
CHU Besançon - Hôpital Jean Minjoz

Besançon, 25030, France
CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre

Bordeaux, 33075, France
Centre Francois Baclesse

Caen, 14076, France
Centre Leon Berard

Lyon, 69373, France
Centrum Onkologii im. Prof. Franciszka ?ukaszczyka

Bydgoszcz, 85-796, Poland
Chonnam National University Hwasun Hospital

Jeollanam-do, 58128, South Korea
Christie Hospital Nhs Trust

Manchester, M2O 4BX, United Kingdom
Emory University

Atlanta, Georgia, 30322, United States
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Hospital Universitari i Politecnic La Fe

Valencia, 46026, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario Clínico San Carlos

Madrid, 28040, Spain
Hospital Universitario Ramon y Cajal

Madrid, 28034, Spain
Hospital Universitario Reina Sofia

Córdoba, Cordoba, 14004, Spain
Hospital Universitario Virgen del Rocio

Seville, 41013, Spain
Hospital de la Santa Creu i Sant Pau

Barcelona, 08025, Spain
Institut Gustave Roussy

Villejuif, 94800, France
Institut Sainte Catherine

Avignon, 84918, France
Klinikum rechts der Isar der TU München

München, 81675, Germany
Medizinische Hochschule Hannover

Hanover, 30625, Germany
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

Nanjing, 210008, China
National Cancer Center

Goyang-si, 10408, South Korea
Peking University First Hospital

Beijing, 100034, China
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
Samsung Medical Center

Seoul, 06351, South Korea
Severance Hospital, Yonsei University Health System

Seoul, 03722, South Korea
Sibley Memorial Hospital

Washington D.C., District of Columbia, 20016, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21287, United States
Studienpraxis Urologie

Nürtingen, 72622, Germany
Sunshine Coast University Hospital

Birtinya, Queensland, 4575, Australia
Szpital Kliniczny im. Heliodora ?wi?cickiego UM w Poznaniu

Późna, 60-569, Poland
Szpital Specjalistyczny Podkarpacki O?rodek Onkologiczny

Brzozów, 36-200, Poland
Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii

Krakow, 31-501, Poland
Tianjin Cancer Hospital

Tianjin, 300060, China
UC Irvine Medical Center

Orange, California, 92868, United States
UT Southwestern Medical Center

Dallas, Texas, 75390-9179, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
Universitätsklinikum "Carl Gustav Carus"

Dresden, 01307, Germany
Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II

Hamburg, 20246, Germany
Universitätsklinikum Ulm

Ulm, 89081, Germany
Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.

RENAL CELL CARCINOMA